Generic Name and Formulations:
Abaloparatide 2000mcg/mL; soln for SC inj.
Radius Health, Inc.
Indications for TYMLOS:
Postmenopausal women with osteoporosis at high risk for fracture.
Limitations Of use:
Cumulative use >2yrs not recommended.
80mcg SC once daily into periumbilical region of abdomen; rotate inj sites. Give supplemental calcium and vitamin D if dietary intake inadequate.
Risk of osteosarcoma.
Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, prior external beam or skeletal implant radiation therapy), pre-existing hypercalcemia or underlying hypercalcemic disorder (eg, primary hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Severe renal impairment: monitor. Pregnancy, nursing mothers: not indicated.
Hormone (human parathyroid hormone related peptide analog).
Hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo; orthostatic hypotension, hypercalcemia, urolithiasis, inj site reactions.
Prefilled pen (1.56mL)—1
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D